Orion's Financial Statement Release for 2022 was published on Thursday, 9 February 2023. The report, related presentation material and link to webcast are available here.
|3/27/2023||Comparative net sales data for 2022 under Orion's new organisational structure and revised accounting practice as of 1 January 2023|
|3/22/2023||Orion Corporation: Organising meeting of the Board of Directors|
|3/22/2023||Decisions taken by Orion Corporation’s Annual General Meeting on 22 March 2023|
|3/21/2023||Orion Corporation: Charman of the Nomination Committee changes|
|3/30/2023||Orion is building a unique pharmaceutical research ecosystem in Finland – using data and artificial intelligence to shorten the development time of new innovative medicines|
|3/23/2023||Orion and Bayer expand clinical development program for darolutamide in prostate cancer|
|3/20/2023||Darolutamide approved for additional prostate cancer indication in China|
|3/1/2023||Darolutamide receives EU approval for additional indication in prostate cancer|
The latest Corporate Governance Statement of Orion Corporation is available at the archive of Corporate Governance Statements.
The product and service portfolio of Orion includes a variety of human pharmaceuticals, veterinary drugs, APIs and contract manufacturing.
Orion is the largest employer in the Finnish pharmaceutical industry. It is considered to be a good and reliable employer, which is also indicated by its lower-than-average employee turnover.